

Virbagen Parvo Lyophilisat und Lösungsmittel zur Herstellung einer Injektionssuspension für Hunde

Authorised

- Canine parvovirus, strain Cornell 780916, Live

Product identification

Medicine name:

Virbagen Parvo Lyophilisat und Lösungsmittel zur Herstellung einer Injektionssuspension für Hunde

Active substance:

Canine parvovirus, strain Cornell 780916, Live

Target species:

Dog

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Canine parvovirus, strain Cornell 780916, Live

100000.00 50% cell culture infectious dose / 1.00 Dose

Pharmaceutical form:

Lyophilisate and solvent for suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AD01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Germany

Package description:

Available only in [German](#)

Available only in [German](#)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)

Marketing authorisation holder:

Virbac Tierarzneimittel GmbH

Marketing authorisation date:

22/12/2005

Manufacturing sites for batch release:

Virbac

Responsible authority:

Paul-Ehrlich-Institut

Authorisation number:

88a/82

Date of authorisation status change:

1/02/2011

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.